drugset

drugset / Trial / NCT04933721

Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies

NCT04933721 ↗

Phase 3 Enrolling by invitation 139 enrolled BioCryst Pharmaceuticals

NaSingle-groupOpen-labelPrevention

Summary

This is a phase 3b open-label study providing access to berotralstat for HAE patients who were previously enrolled in berotralstat studies.

Timeline

Start: 2021-07-23
Primary completion: 2031-08
Completion: 2031-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	berotralstat	Small molecule	150 mg	Oral

Indications